These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37455491)

  • 1. Investigation of the GnRH antagonist degarelix isomerization in biological matrices.
    Ferrazzano L; Tolomelli A; Guryanov I; Macis M; Abel U; Ricci A; Cabri W
    Pharmacol Res Perspect; 2023 Aug; 11(4):e01117. PubMed ID: 37455491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M
    Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
    Broqua P; Riviere PJ; Conn PM; Rivier JE; Aubert ML; Junien JL
    J Pharmacol Exp Ther; 2002 Apr; 301(1):95-102. PubMed ID: 11907162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs.
    Agersø H; Koechling W; Knutsson M; Hjortkjaer R; Karlsson MO
    Eur J Pharm Sci; 2003 Nov; 20(3):335-40. PubMed ID: 14592699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.
    Sari Motlagh R; Abufaraj M; Mori K; Aydh A; Rajwa P; Katayama S; Grossmann NC; Laukhtina E; Mostafai H; Pradere B; Quhal F; Karakiewicz PI; Enikeev DV; Shariat SF
    Eur Urol Oncol; 2022 Apr; 5(2):138-145. PubMed ID: 34301529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonadotropin-releasing hormone antagonist: A real advantage?
    Kimura T; Sasaki H; Akazawa K; Egawa S
    Urol Oncol; 2015 Jul; 33(7):322-8. PubMed ID: 26070474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Gonadotropin-Releasing Hormone Antagonist on Risk of Committing Child Sexual Abuse in Men With Pedophilic Disorder: A Randomized Clinical Trial.
    Landgren V; Malki K; Bottai M; Arver S; Rahm C
    JAMA Psychiatry; 2020 Sep; 77(9):897-905. PubMed ID: 32347899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GnRH Antagonist Degarelix Suppresses Gonadotropin Secretion and Pituitary Sensitivity in Midgestation Sheep Fetuses.
    Amodei R; Jonker SS; Whitler W; Estill CT; Roselli CE
    Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34958103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.
    Samant MP; Gulyas J; Hong DJ; Croston G; Rivier C; Rivier J
    J Med Chem; 2005 Jul; 48(15):4851-60. PubMed ID: 16033265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
    Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
    Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth.
    Sakai M; Martinez-Arguelles DB; Patterson NH; Chaurand P; Papadopoulos V
    PLoS One; 2015; 10(3):e0120670. PubMed ID: 25811175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation.
    Wang C; Ma Y; Feng S; Liu K; Zhou N
    J Pept Sci; 2015 Jul; 21(7):569-76. PubMed ID: 25851250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degarelix: a new approach for the treatment of prostate cancer.
    Persson BE; Kold Olesen T; Jensen JK
    Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression.
    Cucchiara V; Yang JC; Liu C; Adomat HH; Tomlinson Guns ES; Gleave ME; Gao AC; Evans CP
    Mol Cancer Ther; 2019 Oct; 18(10):1811-1821. PubMed ID: 31341032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
    Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
    Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model.
    Hopmans SN; Duivenvoorden WC; Werstuck GH; Klotz L; Pinthus JH
    Urol Oncol; 2014 Nov; 32(8):1126-34. PubMed ID: 25242517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological activity of GnRH antagonists modified at position 3 with 3-(2-methoxy-5-pyridyl)-alanine.
    Samant MP; Miller C; Hong DJ; Koerber SC; Croston G; Rivier CL; Rivier JE
    J Pept Res; 2005 Feb; 65(2):284-91. PubMed ID: 15705170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.